Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,072 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG. Moreau P, et al. Among authors: kaiser m. Lancet Oncol. 2021 Mar;22(3):e105-e118. doi: 10.1016/S1470-2045(20)30756-7. Lancet Oncol. 2021. PMID: 33662288 Review.
Proteasome: an emerging target for cancer therapy.
Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C, Rosche M, Possinger K, Sezer O. Zavrski I, et al. Among authors: kaiser m. Anticancer Drugs. 2005 Jun;16(5):475-81. doi: 10.1097/00001813-200506000-00002. Anticancer Drugs. 2005. PMID: 15846112 Review.
Bone markers in multiple myeloma.
Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O. Heider U, et al. Among authors: kaiser m. Eur J Cancer. 2006 Jul;42(11):1544-53. doi: 10.1016/j.ejca.2005.11.034. Epub 2006 Jun 9. Eur J Cancer. 2006. PMID: 16765040 Review.
Angiogenesis in multiple myeloma.
Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O. Jakob C, et al. Among authors: kaiser m. Eur J Cancer. 2006 Jul;42(11):1581-90. doi: 10.1016/j.ejca.2006.02.017. Epub 2006 Jun 23. Eur J Cancer. 2006. PMID: 16797965 Review.
Proteasome as an emerging therapeutic target in cancer.
Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O. Zavrski I, et al. Among authors: kaiser m. Curr Pharm Des. 2007;13(5):471-85. doi: 10.2174/138161207780162908. Curr Pharm Des. 2007. PMID: 17348844 Review.
2,072 results